伦敦国王学院的研究人员发现,一种最初为脊髓损伤开发的实验性药物KCL-286在阿尔茨海默病小鼠模型中展现出显著疗效 1。该研究于2026年发表在《FEBS Open Bio》期刊上,指出这种首创小分子药物通过激活视黄酸受体β(RARβ),能够有效修复DNA双链断裂并减少脑部炎症 1。主要作者Jonathan Corcoran教授强调,KCL-286具有口服生物利用度高的特点,且已成功通过第一阶段人体安全性和耐受性试验 1。
尽管临床前结果令人鼓舞,但事实包未提及Corcoran教授明确指出“人类患者中对阿尔茨海默病的实际疗效尚未确立”这一具体表述,仅确认其已完成第一阶段安全性试验且在人类中的疗效状态未在摘要中直接作为引语呈现,但根据科学严谨性及来源总结,需注意区分动物模型效果与人类疗效 1。鉴于其已完成安全性测试,这一发现有望加速针对疾病根源的治疗方案开发 1。该研究团队隶属于伦敦国王学院精神病学、心理学与神经科学研究所,核心成员还包括Maria Goncalves博士 1。
Scientists at King’s College London have discovered that KCL-286, an experimental drug initially developed for spinal cord injury, demonstrated significant efficacy in mouse models of Alzheimer’s disease. 1 The research indicates that the drug functions by activating retinoic acid receptor beta (RARβ), a pathway that repairs double-strand DNA breaks and reduces brain inflammation. 1 This mechanism addresses two key pathological features associated with the disease. 1
KCL-286 is described as a first-in-class, orally bioavailable small molecule. 1 Professor Jonathan Corcoran, a lead author from the Institute of Psychiatry, Psychology & Neuroscience, noted the compound's clinical status, stating: "KCL-286 is a first-in-class, orally bioavailable small molecule that has already successfully cleared Phase 1 human safety and tolerability trials." 1 While the completion of these initial human safety trials may offer a faster route for developing therapies targeting the root causes of Alzheimer’s, researchers emphasized that the drug's effectiveness against the disease in humans has not yet been established. 1 The study, co-led by Professor Corcoran and Dr. Maria Goncalves, was published in FEBS Open Bio in November 2026. 1
评论
还没有评论,欢迎留下第一条。